Related Experiment Video
Updated: Oct 23, 2025
07:35
Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
11.6K
TAMEing ADPKD with metformin: safe and effective?
Albert C M Ong1, Ron T Gansevoort2
1Kidney Genetics Group, Academic Nephrology Unit, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield Medical School, Beech Hill Road, Sheffield, UK.
Kidney International
|August 23, 2021
Summary
Metformin, a diabetes drug, shows promise for slowing autosomal dominant polycystic kidney disease (ADPKD) progression. The TAME PKD trial found metformin safe and well-tolerated in early-stage ADPKD patients.
Area of Science:
- Nephrology
- Pharmacology
- Genetics
Background:
- Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic disorder.
- Current treatments for ADPKD primarily manage symptoms and slow disease progression.
- Metformin, a widely used type 2 diabetes medication, has shown potential in preclinical models for ADPKD.
Purpose of the Study:
- To evaluate the safety and tolerability of metformin in patients with early-stage ADPKD.
- To assess the potential of metformin as a disease-modifying therapy for ADPKD.
Main Methods:
- The Trial of Administration of Metformin in PKD (TAME PKD) was a phase 2 randomized controlled trial.
- Participants were patients in the early stages of autosomal dominant polycystic kidney disease.
- The study investigated the safety and tolerability profiles of metformin.
Main Results:
- Metformin was found to be safe and well-tolerated in patients with early-stage ADPKD.
- The findings support further investigation into metformin's efficacy for ADPKD.
Conclusions:
- Metformin is a viable therapeutic option for further study in autosomal dominant polycystic kidney disease.
- These results inform the design and expectations for upcoming phase 3 trials in ADPKD.
More Related Videos
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
353
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
353
01:25Chronic Kidney Disease I: Introduction
277
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
277
01:28Chronic Kidney Disease III: Interprofessional Care
148
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
148
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
36
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
36
01:24Chronic Kidney Disease II: Clinical Manifestations
182
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
182
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
40
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
40